Tumor cell complementation groups based on myogenic potential: Evidence for inactivation of loci required for basic helix-loop-helix protein activity

Molecular and Cellular Biology

Volumn 16, Issue 7, 1996, Pages 3901-3908

  Gerber, Anthony N ^a   Tapscott, Stephen J ^b,c  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MYOD PROTEIN;

ARTICLE; CELL FUSION; CONTROLLED STUDY; GENE LOCUS; GENETIC COMPLEMENTATION; GLIOBLASTOMA; HUMAN; HUMAN CELL; MEDULLOBLASTOMA; MUSCLE CELL; MUSCLE DEVELOPMENT; NEUROBLASTOMA; PRIORITY JOURNAL; SKELETAL MUSCLE; TUMOR GROWTH;

EID: 0029980077     PISSN: 02707306     EISSN: None     Source Type: Journal    
DOI: 10.1128/MCB.16.7.3901     Document Type: Article

References (70)

1. Airey, J. A., M. D. Baring, and J. L. Sutko. 1991. Ryanodine receptor protein is expressed during differentiation in the muscle cell lines BC3H1 and C2C12. Dev. Biol. 148:365-374.
2. Auffray, C., and F. Rougeon. 1980. Purification of mouse immunoglobulin heavy-chain messenger RNAs from total myeloma tumor RNA. Eur. J. Biochem. 107:303-314.
3. Azar, C. G., N. J. Scavarda, C. P. Reynolds, and G. M. Brodeur. 1990. Multiple defects of the nerve growth factor receptor in human neuroblastomas. Cell Growth Differ. 1:421-428.
4. Bader, S. A., C. Fasching, G. M. Brodeur, and E. J. Stanbridge. 1991. Dissociation of suppression of tumorigenicity and differentiation in vitro effected by transfer of single human chromosomes into human neuroblastoma cells. Cell Growth Differ. 2:245-255.
5. Bengal, E., L. Ransone, R. Scharfmann, V. J. Dwarki, S. J. Tapscott, H. Weintraub, and I. M. Verma. 1992. Functional antagonism between c-Jun and MyoD proteins: a direct physical association. Cell 68:507-519.
6. Blanar, M. A., P. H. Crossley, K. G. Peters, E. Steingrimsson, N. G. Copeland, N. A. Jenkins, G. R. Martin, and W. J. Rutter. 1995. Mesol, a basic-helix-loop-helix protein involved in mammalian presomitic mesoderm development. Proc. Natl. Acad. Sci. USA 92:5870-5874.
7. Brennan, T. J., D. G. Edmondson, L. Li, and E. N. Olson. 1991. Transforming growth factor beta represses the actions of myogenin through a mechanism independent of DNA binding. Proc. Natl. Acad. Sci. USA 88:3822-3826.
8. Carreau, M., E. Eveno, X. Quilliet, O. Chevalier-Lagente, A. Benoit, B. Tanganelli, M. Stefanini, W. Vermeulen, J. H. Hoeijmakers, A. Sarasin, et al. 1995. Development of a new easy complementation assay for DNA repair deficient human syndromes using cloned repair genes. Carcinogenesis 16:1003-1009.
9. Carriage, M. T., and D. E. Henson. 1995. The histologic grading of cancer. Cancer 75:406-421.
10. Cerosaletti, K. M., M. H. Shapero, and R. E. Fournier. 1995. Cloning mammary cell cDNAs from 17q12-q23 using interspecific somatic cell hybrids and subtractive hybridization. Genomics 25:226-237.
11. Chen, P., N. Ellmore, and B. E. Weissman. 1994. Functional evidence for a second tumor suppressor gene on human chromosome 17. Mol. Cell. Biol. 14:534-542.
12. Choi, J., M. L. Costa, C. S. Mermelstein, C. Chagas, S. Holtzer, and H. Holtzer. 1990. MyoD converts primary dermal fibroblasts, chondroblasts, smooth muscle and retinal pigment epithelial cells into striated, monoucleated myoblasts and multinucleated myotubes. Proc. Natl. Acad. Sci. USA 87:7988-7992.
13. Clark, J., P. J. Rocques, T. Braun, E. Bober, H. H. Arnold, C. Fisher, C. Fletcher, K. Brown, B. A. Gusterson, R. L. Carter, et al. 1991. Expression of members of the myf gene family in human rhabdomyosarcomas. Br. J. Cancer 64:1039-1042.
14. Cserjesi, P., D. Brown, K. L. Ligon, G. E. Lyons, N. G. Copeland, D. J. Gilbert, N. A. Jenkins, and E. N. Olson. 1995. Scleraxis: a basic helix-loop-helix protein that prefigures skeletal formation during mouse embryogenesis. Development 121:1099-1110.
15. Davis, R. L., and H. Weintraub. 1992. Acquisition of myogenic specificity by replacement of three amino acid residues from MyoD into E12. Science 256:1027-1030.
16. Dienstman, S. R., and H. Holtzer. 1977. Skeletal myogenesis. Control of proliferation in a normal cell lineage. Exp. Cell Res. 107:355-364.
17. Felsenfeld, A. L., M. Curry, and C. B. Kimmel. 1991. The fub-1 mutation blocks initial myofibril formation in zebrafish muscle pioneer cells. Dev. Biol. 148:23-30.
18. Giangrande, A. 1995. Proneural genes influence gliogenesis in Drosophila. Development 121:429-438.
19. Goyette, M. C., K. Cho, C. L. Fasching, D. B. Levy, K. W. Kinzler, C. Paraskeva, B. Vogelstein, and E. J. Stanbridge. 1992. Progression of colorectal cancer is associated with multiple tumor suppressor gene defects but inhibition of tumorigenicity is accomplished by correction of any single defect via chromosome transfer. Mol. Cell. Biol. 12:1387-1395.
20. Grana, X., and E. P. Reddy. 1995. Cell cycle control in mammalian cells: role of cyclins, cyclin dependent kinases (CDKs), growth suppressor genes and cyclin-dependent kinase inhibitors (CKIs). Oncogene 11:211-219.
21. Gu, W., J. W. Schneider, G. Condorelli, S. Kaushal, V. Mahdavi, and B. Nadal-Ginard. 1993. Interaction of myogenic factors and the retinoblastoma protein mediates muscle cell commitment and differentiation. Cell 72:309-324.
22. Guillemot, F., L. C. Lo, J. E. Johnson, A. Auerbach, D. J. Anderson, and A. L. Joyner. 1993. Mammalian achaete-scute homolog 1 is required for the early development of olfactory and autonomic neurons. Cell 75:463-476.
23. Guillemot, F., A. Nagy, A. Auerbach, J. Rossant, and A. L. Joyner. 1994. Essential role of Mash-2 in extraembryonic development. Nature (London) 371:333-336.
24. Habraken, Y., P. Sung, L. Prakash, and S. Prakash. 1994. Human xeroderma pigmentosum group G gene encodes a DNA endonuclease. Nucleic Acids Res. 22:3312-3316.
25. Halevy, O., B. G. Novitch, D. B. Spicer, S. X. Skapek, J. Rhee, G. J. Hannon, D. Beach, and A. B. Lassar. 1995. Correlation of terminal cell cycle arrest of skeletal muscle with induction of p21 by MyoD. Science 267:1018-1021.
26. He, J., J. R. Allen, V. P. Collins, M. J. Allalunis-Turner, R. Godbout, R. S. Day, and C. D. James. 1994. CDK4 amplification is an alternative mechanism to p16 gene homozygous deletion in glioma cell lines. Cancer Res. 54:5804-5807.
27. Hock, R. A., and A. D. Miller. 1986. Retrovirus-mediated transfer and expression of drug resistance genes in human haematopoietic progenitor cells. Nature (London) 320:275-277.
28. Holl, T., P. Kleihues, M. G. Yasargil, and O. D. Wiestler. 1991. Cerebellar medullomyoblastoma with advanced neuronal differentiation and hamartomatous component. Acta Neuropathol. 82:408-413.
29. Hong, L. L., L. Johannsen, and J. M. Krueger. 1991. Modulation of human leukocyte antigen DR expression in glioblastoma cells by interferon gamma and other cytokines. J. Neuroimmunol. 35:139-152.
30. Hosoi, H., T. Sugimoto, Y. Hayashi, T. Inaba, Y. Horii, H. Morioka, S. Fushiki, M. Hamazaki, and T. Sawada. 1992. Differential expression of myogenic regulatory genes, MyoD1 and myogenin, in human rhabdomyosarcoma sublines. Int. J. Cancer 50:977-983.
31. Jarman, A. P., Y. Sun, L. Y. Jan, and Y. N. Jan. 1995. Role of the proneural gene, atonal, in formation of Drosophila chordotonal organs and photoreceptors. Development 121:2019-2030.
32. Jaspers, N. G., and D. Bootsma. 1982. Genetic heterogeneity in ataxiatelangiectasia studied by cell fusion. Proc. Natl. Acad. Sci. USA 79:2641-2644.
33. Kamb, A., N. A. Gruis, J. Weaver-Feldhaus, Q. Liu, K. Harshman, S. V. Tavtigian, E. Stockert, R. S. Day, B. E. Johnson, and M. H. Skolnick. 1994. A cell cycle regulator potentially involved in genesis of many tumor types. Science 264:436-440.
34. Kaur, G. P., and R. S. Athwal. 1993. Complementation of DNA repair defect in xeroderma pigmentosum cells of group C by the transfer of human chromosome 5. Soma. Cell Mol. Genet. 19:83-93.
35. Kraemer, K. H., H. G. Coon, R. A. Petinga, S. F. Barrett, A. E. Rahe, and J. H. Robbins. 1975. Genetic heterogeneity in xeroderma pigmentosum: complementation groups and their relationship to DNA repair rates. Proc. Natl. Acad. Sci. USA 72:59-63.
36. Lee, J. E., S. M. Hollenberg, L. Snider, D. L. Turner, N. Lipnick, and H. Weintraub. 1995. Conversion of Xenopus ectoderm into neurons by NeuroD, a basic helix-loop-helix protein. Science 268:836-844.
37. Li, L., J. C. Chambard, M. Karin, and E. N. Olson. 1992. Fos and Jun repress transcriptional activation by myogenin and MyoD: the amino terminus of Jun can mediate repression. Genes Dev. 6:676-689.
38. Li, L., J. Zhou, G. James, R. Heller-Harrison, M. P. Czech, and E. N. Olson. 1992. FGF inactivates myogenic helix-loop-helix proteins through phosphorylation of a conserved protein kinase C site in their DNA-binding domains. Cell 71:1181-1194.
39. Lukas, J., D. Parry, L. Aagaard, D. J. Mann, J. Bartkova, M. Strauss, G. Peters, and J. Bartek. 1995. Retinoblasloma-protein-dependent cell-cycle inhibition by the tumour suppressor p16. Nature (London) 375:503-506.
40. Miller, A. D., and G. J. Rosman. 1989. Improved retroviral vectors for gene transfer and expression. BioTechniques 7:980-982, 984-986, 989-990.
41. Miner, J. H., and B. J. Wold. 1991. c-myc inhibition of MyoD and myogenin-initiated myogenic differentiation. Mol. Cell. Biol. 11:2842-2851.
42. Molkentin, J. D., B. L. Black, J. F. Martin, and E. N. Olson. 1995. Cooperative activation of muscle specific gene expression by MEF2 and myogenic bHLH proteins. Cell 83:1125-1136.
43. Neuhold, L. A., and B. Wold. 1993. HLH forced dimers: tethering MyoD to E47 generates a dominant positive myogenic factor insulated from negative regulation by Id. Cell 74:1033-1042.
44. Ogawa, S., A. Hangaishi, S. Miyawaki, S. Hirosawa, Y. Miura, K. Takeyama, N. Kamada, S. Ohtake, N. Uike, C. Shimazaki, et al. 1995. Loss of the cyclin-dependent kinase 4-inhibitor (p16; MTS1) gene is frequent in and highly specific to lymphoid tumors in primary human hematopoietic malignancies. Blood 86:1548-1556.
45. Olson, E. N., and W. H. Klein. 1994. bHLH factors in muscle development: dead lines and commitments, what to leave in and what to leave out. Genes Dev. 8:1-8.
46. Peng, H. Q., D. Bailey, D. Bronson, P. E. Goss, and D. Hogg. 1995. Loss of heterozygosity of tumor suppressor genes in testis cancer. Cancer Res. 55:2871-2875.
47. Pereira-Smith, O. M., and J. R. Smith. 1995. Genetic analysis of indefinite division in human cells: identification of four complementation groups. Proc. Natl. Acad. Sci. USA 85:6042-6046.
48. Prados, J., C. Melguizo, J. E. Fernandez, A. E. Aranega, and A. Aranega. 1993. Actin, tropomyosin and alpha-actinin as markers of differentiation in human rhabdomyosarcoma cell lines induced with dimethyl sulfoxide. Cell. Mol. Biol. 39:525-536.
49. Raza, A., N. Yousuf, S. A. Bokhari, A. Mehdi, M. Masterson, B. Lampkin, G. Yanik, C. Mazewski, S. Khan, and H. Preisler. 1992. Contribution of in vivo proliferation/differentiation studies toward the development of a combined functional and morphologic system of classification of neoplastic diseases. Cancer 69:1557-1566.
50. Sancho, S., T. Mongini, K. Tanji, S. J. Tapscott, W. F. Walker, H. Weintraub, A. D. Miller, and A. F. Miranda. 1993. Analysis of dystrophin expression after activation of myogenesis in amniocytes, chorionic-villus cells, and fibroblasts. A new method for diagnosing Duchenne's muscular dystrophy. N. Engl. J. Med. 329:915-920.
51. Scherly, D., T. Nouspikel, J. Corlet, C. Ucla, A. Bairoch, and S. G. Clarkson. 1993. Complementation of the DNA repair defect in xeroderma pigmentosum group G cells by a human cDNA related to yeast RAD2. Nature (London) 363:182-185.
52. Schiffer, D., M. T. Giordana, S. Pezzotta, T. Pezzulo, and M. C. Vigliani. 1992. Medullomyoblastoma: report of two cases. Child's Nerv. Syst. 8:268-272.
53. Schmidt, E. E., K. Ichimura, G. Reifenberger, and V. P. Collins. 1994. CDKN2 (p16/MTS1) gene deletion or CDK4 amplification occurs in the majority of glioblastomas. Cancer Res. 54:6321-6324.
54. Sherr, C. J., and J. M. Roberts. 1995. Inhibitors of mammalian C1 cyclin-dependent kinases. Genes Dev. 9:1149-1163.
55. Silber, J. R., M. S. Bobola, T. G. Ewers, M. Muramoto, and M. S. Berger. 1992. O6-alkylguanine DNA-alkyltransferase is not a major determinant of sensitivity to 1,3-bis(2-chloroethyl)-1-nitrosourea in four medulloblastoma cell lines. Oncol. Res. 4:241-248.
56. Silbergeld, D. L., F. Ali-Osman, and H. R. Winn. 1991. Induction of transformational changes in normal endothelial cells by cultured human astrocytoma cells. J. Neurosurg. 75:604-612.
57. Skapek, S. X., J. Rhee, D. B. Spicer, and A. B. Lassar. 1995. Inhibition of myogenic differentiation in proliferating myoblasts by cyclin D1-dependent kinase. Science 267:1022-1024.
58. Sorensen, P. H., H. Shimada, X. F. Liu, J. F. Lim, G. Thomas, and T. J. Triche. 1995. Biphenotypic sarcomas with myogenic and neural differentiation express the Ewing's sarcoma EWS/FLI1 fusion gene. Cancer Res. 55:1385-1392.
59. Sperduto, P. W., C. W. Song, and S. H. Levitt. 1993. The in vitro radiosensitization of human glioblastoma with pentoxifylline. Am. J. Clin. Oncol. 16:407-411.
60. Stegmaier, K., S. Pendse, G. F. Barker, P. Bray-Ward, D. C. Ward, K. T. Montgomery, K. S. Krauter, C. Reynolds, J. Sklar, M. Donnelly, et al. 1995. Frequent loss of heterozygosity at the TEL gene locus in acute lymphoblastic leukemia of childhood. Blood 86:38-44.
61. Su, H. Y., T. J. Bos, F. S. Monteclaro, and P. K. Vogt. 1991. Jun inhibits myogenic differentiation. Oncogene 6:1759-1766.
62. Tapscott, S. J., M. J. Thayer, and H. Weintraub. 1993. Deficiency in rhabdomyosarcomas of a factor required for MyoD activity and myogenesis. Science 259:1450-1453.
63. Vaidya, T. B., C. M. Weyman, D. Teegarden, C. L. Ashendel, and E. J. Taparowsky. 1991. Inhibition of myogenesis by the H-ras oncogene: implication of a role for protein kinase C. J. Cell Biol. 114:809-820.
64. Weeda, G., J. Wiegant, M. van der Ploeg, A. H. Geurts van Kessel, A. J. van der Eb, and J. H. Hoeijmakers. 1991. Localization of the xeroderma pigmentosum group B-correcting gene ERCC3 to human chromosome 2q21. Genomics 10:1035-1040.
65. Weintraub, H. 1993. The MyoD family and myogenesis: redundancy, networks, and thresholds. Cell 75:1241-1244.
66. Weintraub, H., V. J. Dwarki, I. Verma, R. Davis, S. Hollenberg, L. Snider, A. Lassar, and S. J. Tapscott. 1991. Muscle-specific transcriptional activation by MyoD. Genes Dev. 5:1377-1386.
67. Weintraub, H., S. Hauschka, and S. J. Tapscott. 1991. The MCK enhancer contains a p53 responsive element. Proc. Natl. Acad. Sci. USA 88:4570-4571.
68. Weintraub, H., S. J. Tapscott, R. L. Davis, M. Thayer, M. Adam, A. Lassar, and A. D. Miller. 1989. Activation of muscle-specific genes in pigment, nerve, fat, liver, and fibroblast cell lines by forced expression of MyoD. Proc. Natl. Acad. Sci. USA 86:5434-5438.
69. Xiao, S., D. Li, J. M. Corson, J. Vijg, and J. A. Fletcher. 1995. Codeletion of p15 and p16 genes in primary non-small cell lung carcinoma. Cancer Res. 55:2968-2971.
70. Zakrzewski, S., and K. Sperling. 1980. Genetic heterogeneity of Fanconi's anemia demonstrated by somatic cell hybrids. Hum. Genet 56:81-84.